Cargando…

Ketone bodies in right ventricular failure: A unique therapeutic opportunity

BACKGROUND: Ketone bodies are pleotropic metabolites that play important roles in multiple biological processes ranging from bioenergetics to inflammation regulation via suppression of the NLRP3 inflammasome, and epigenetic modifications. Ketone bodies are elevated in left ventricular failure (LVF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Blake, Madelyn, Puchalska, Patrycja, Kazmirczak, Felipe, Blake, Jeffrey, Moon, Ryan, Thenappan, Thenappan, Crawford, Peter A., Prins, Kurt W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695997/
http://dx.doi.org/10.1016/j.heliyon.2023.e22227
_version_ 1785154476988956672
author Blake, Madelyn
Puchalska, Patrycja
Kazmirczak, Felipe
Blake, Jeffrey
Moon, Ryan
Thenappan, Thenappan
Crawford, Peter A.
Prins, Kurt W.
author_facet Blake, Madelyn
Puchalska, Patrycja
Kazmirczak, Felipe
Blake, Jeffrey
Moon, Ryan
Thenappan, Thenappan
Crawford, Peter A.
Prins, Kurt W.
author_sort Blake, Madelyn
collection PubMed
description BACKGROUND: Ketone bodies are pleotropic metabolites that play important roles in multiple biological processes ranging from bioenergetics to inflammation regulation via suppression of the NLRP3 inflammasome, and epigenetic modifications. Ketone bodies are elevated in left ventricular failure (LVF) and multiple approaches that increase ketone concentrations exert advantageous cardiac effects in rodents and humans. However, the relationships between ketone bodies and right ventricular failure (RVF) are relatively unexplored. METHODS: 51 PAH patients were dichotomized into preserved or impaired RV function based on a cardiac index of 2.2 L/min/m(2). Impaired RV function patients were further segmented into intermediate or severe RV dysfunction based on a right atrial pressure of 8 mm Hg. Serum ketone bodies acetoacetate (AcAc) and beta-hydroxybutyrate (βOHB) were quantified using ultra performance liquid chromatography and mass spectrometry. In rodent studies, male Sprague Dawley rats were assigned to three groups: control (saline injection), monocrotaline (MCT) standard chow diet (MCT-Standard), and MCT ketogenic diet (MCT-Keto). Immunoblots and confocal microscopy probed macrophage NLRP3 activation in RV extracts and sections. RV fibrosis was determined by Picrosirus Red. Echocardiography evaluated RV function. Pulmonary arteriole remodeling was assessed from histological specimens. RESULTS: Human RVF patients lacked a compensatory ketosis as serum AcAc and βOHB levels were not associated with hemodynamic, echocardiographic, or biochemical measures of RV dysfunction. In rodent studies, AcAc and βOHB levels were also not elevated in MCT-mediated RVF, but the ketogenic diet significantly increased AcAc and βOHB levels. MCT-Keto exhibited suppressed NLRP3 activation with a reduction in NLRP3, ASC (apoptosis-associated speck-like protein), pro-caspase-1, and interleukin-1 beta on immunoblots. Moreover, the number of ASC-positive macrophage in RV sections was reduced, RV fibrosis was blunted, and RV function was augmented in MCT-Keto rats. CONCLUSION: The ketogenic response is blunted in pulmonary arterial hypertension (PAH) patients with RVF. In the MCT rat model of PAH-mediated RVF, a dietary-induced ketosis improves RV function, suppresses NLRP3 inflammasome activation, and combats RV fibrosis. The summation of these data suggest ketogenic therapies may be particularly efficacious in RVF, and therefore future studies evaluating ketogenic interventions in human RVF are warranted.
format Online
Article
Text
id pubmed-10695997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106959972023-12-06 Ketone bodies in right ventricular failure: A unique therapeutic opportunity Blake, Madelyn Puchalska, Patrycja Kazmirczak, Felipe Blake, Jeffrey Moon, Ryan Thenappan, Thenappan Crawford, Peter A. Prins, Kurt W. Heliyon Research Article BACKGROUND: Ketone bodies are pleotropic metabolites that play important roles in multiple biological processes ranging from bioenergetics to inflammation regulation via suppression of the NLRP3 inflammasome, and epigenetic modifications. Ketone bodies are elevated in left ventricular failure (LVF) and multiple approaches that increase ketone concentrations exert advantageous cardiac effects in rodents and humans. However, the relationships between ketone bodies and right ventricular failure (RVF) are relatively unexplored. METHODS: 51 PAH patients were dichotomized into preserved or impaired RV function based on a cardiac index of 2.2 L/min/m(2). Impaired RV function patients were further segmented into intermediate or severe RV dysfunction based on a right atrial pressure of 8 mm Hg. Serum ketone bodies acetoacetate (AcAc) and beta-hydroxybutyrate (βOHB) were quantified using ultra performance liquid chromatography and mass spectrometry. In rodent studies, male Sprague Dawley rats were assigned to three groups: control (saline injection), monocrotaline (MCT) standard chow diet (MCT-Standard), and MCT ketogenic diet (MCT-Keto). Immunoblots and confocal microscopy probed macrophage NLRP3 activation in RV extracts and sections. RV fibrosis was determined by Picrosirus Red. Echocardiography evaluated RV function. Pulmonary arteriole remodeling was assessed from histological specimens. RESULTS: Human RVF patients lacked a compensatory ketosis as serum AcAc and βOHB levels were not associated with hemodynamic, echocardiographic, or biochemical measures of RV dysfunction. In rodent studies, AcAc and βOHB levels were also not elevated in MCT-mediated RVF, but the ketogenic diet significantly increased AcAc and βOHB levels. MCT-Keto exhibited suppressed NLRP3 activation with a reduction in NLRP3, ASC (apoptosis-associated speck-like protein), pro-caspase-1, and interleukin-1 beta on immunoblots. Moreover, the number of ASC-positive macrophage in RV sections was reduced, RV fibrosis was blunted, and RV function was augmented in MCT-Keto rats. CONCLUSION: The ketogenic response is blunted in pulmonary arterial hypertension (PAH) patients with RVF. In the MCT rat model of PAH-mediated RVF, a dietary-induced ketosis improves RV function, suppresses NLRP3 inflammasome activation, and combats RV fibrosis. The summation of these data suggest ketogenic therapies may be particularly efficacious in RVF, and therefore future studies evaluating ketogenic interventions in human RVF are warranted. Elsevier 2023-11-15 /pmc/articles/PMC10695997/ http://dx.doi.org/10.1016/j.heliyon.2023.e22227 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Blake, Madelyn
Puchalska, Patrycja
Kazmirczak, Felipe
Blake, Jeffrey
Moon, Ryan
Thenappan, Thenappan
Crawford, Peter A.
Prins, Kurt W.
Ketone bodies in right ventricular failure: A unique therapeutic opportunity
title Ketone bodies in right ventricular failure: A unique therapeutic opportunity
title_full Ketone bodies in right ventricular failure: A unique therapeutic opportunity
title_fullStr Ketone bodies in right ventricular failure: A unique therapeutic opportunity
title_full_unstemmed Ketone bodies in right ventricular failure: A unique therapeutic opportunity
title_short Ketone bodies in right ventricular failure: A unique therapeutic opportunity
title_sort ketone bodies in right ventricular failure: a unique therapeutic opportunity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695997/
http://dx.doi.org/10.1016/j.heliyon.2023.e22227
work_keys_str_mv AT blakemadelyn ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT puchalskapatrycja ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT kazmirczakfelipe ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT blakejeffrey ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT moonryan ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT thenappanthenappan ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT crawfordpetera ketonebodiesinrightventricularfailureauniquetherapeuticopportunity
AT prinskurtw ketonebodiesinrightventricularfailureauniquetherapeuticopportunity